Skip to main content
logo
Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
9.37
+0.01 (0.11%)
Nov 9, 2026, 4:00 PM EST - Market closed

Pelthos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
43.316.8----
Revenue Growth
-8300.27%----
Cost of Revenue
10.585.221.18-0.390.21
Gross Profit
32.7311.58-1.18--0.39-0.21
Selling, General & Admin
84.3541.436.394.281.930.63
Research & Development
---2.58--
Amortization of Goodwill & Intangibles
3.631.56----
Operating Expenses
87.9842.996.396.861.930.63
Operating Income
-55.25-31.41-7.57-6.86-2.32-0.84
Interest Expense
-7.4-3.01-0.79-0.52-0.14-0
Interest & Investment Income
0.010.010.4---
Other Non Operating Income (Expenses)
-28.32-14.98----
EBT Excluding Unusual Items
-90.97-49.4-7.96-7.38-2.46-0.84
Merger & Restructuring Charges
-1.02-1.02----
Asset Writedown
-0.29-0.29----
Other Unusual Items
-1.5----0.24
Pretax Income
-93.78-50.71-7.96-7.38-2.46-0.6
Income Tax Expense
-7.39-7.39----
Net Income
-86.39-43.32-7.96-7.38-2.46-0.6
Net Income to Common
-86.39-43.32-7.96-7.38-2.46-0.6
Net Income Growth
------
Shares Outstanding (Basic)
32100-
Shares Outstanding (Diluted)
32100-
Shares Change
435.44%237.34%336.69%193.25%--
EPS (Basic)
-26.36-23.04-14.27-57.82-56.48-
EPS (Diluted)
-26.36-23.04-14.27-57.82-56.48-
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-42.6-22.69-5.79-0.98-1.57-1.59
Free Cash Flow Per Share
-13.00-12.06-10.39-7.68-36.00-
Gross Margin
75.58%68.94%----
Operating Margin
-127.60%-187.01%----
Profit Margin
-199.50%-257.93%----
Free Cash Flow Margin
-98.37%-135.09%----
EBITDA
--29.12---1.63-
EBITDA Margin
--173.40%----
D&A For EBITDA
-2.29--0.69-
EBIT
-55.25-31.41-7.57-6.86-2.32-0.84
EBIT Margin
-127.60%-187.01%----
Revenue as Reported
43.316.8----
SEC Filings: 10-K · 10-Q